# Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy

> **NCT01014325** · PHASE3 · UNKNOWN · sponsor: **Roxall Medizin** · enrollment: 130 (estimated)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** Allergen extract
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01014325
- **Lead sponsor:** Roxall Medizin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01014325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01014325, "Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01014325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*